arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

PALISADE BIO, INC.

PALI
$2.11 ▲ +0.01 (+0.72%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
67 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
24
Health
Poor
Neutral
auto_awesome

Analytical Summary

PALISADE BIO, INC. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $442.4M
Dividend Yield
Revenue Growth None
Op. Margin
ROIC -6.7%
FCF / Share $-0.02
Trailing P/E
Price / Book 2.8x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-9.60M
↓ -330.5%
FCF / Share Free cash flow per share
$-0.02
↑ +96.2%
Long-Term Debt Long-term obligations
$568.00K
↓ -50.2%

Health Breakdown

Returns
32
Financial Health
3
Cash Quality
46

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters